Histone Deacetylase 6 Selective Inhibitors for the Treatment of Cisplatin-Induced Peripheral Neuropathy
Disclosed are methods for treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor.
1 . A method of treating cisplatin-induced peripheral neuropathy in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 selective inhibitor, to thereby treat the cisplatin-induced peripheral neuropathy.
2 . The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is compound 001:
or a pharmaceutically acceptable salt thereof.
3 . The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin.
4 . The method of claim 1 , wherein the histone deacetylase 6 selective inhibitor is administered before or after administering cisplatin.
5 . The method of claim 1 , wherein the cisplatin-induced peripheral neuropathy exists in the subject prior to administering the histone deacetylase 6 selective inhibitor.
6 . A method of treating cisplatin-induced pain or cisplatin-induced numbness, comprising administering to a subject in need thereof an effective amount of a histone deacetylase 6 selective inhibitor to thereby treat the cisplatin-induced pain in the subject.
7 . The method of claim 6 , wherein the histone deacetylase 6 selective inhibitor is compound 001:
or a pharmaceutically acceptable salt thereof.
8 . The method of claim 6 , wherein the histone deacetylase 6 selective inhibitor is co-administered with cisplatin.
9 . The method of claim 6 , wherein the histone deacetylase 6 selective inhibitor is administered before or after administering cisplatin.
10 . The method of claim 6 , wherein the cisplatin-induced peripheral neuropathy exists in the subject prior to administering the histone deacetylase 6 selective inhibitor.
11 . A method for restoring the loss of intra-epidermal nerve fiber (IENF) in a subject, comprising administering to the subject an effective amount of a histone deacetylase 6 selective inhibitor.
12 . The method of claim 11 , wherein the loss of intra-epidermal nerve fiber is the result of administering cisplatin to the subject.
13 . The method of claim 12 , wherein the administration of the histone deacetylase 6 selective inhibitor to the subject occurs during or after administering cisplatin.
14 . The method of claim 11 , wherein the histone deacetylase 6 selective inhibitor is compound 001:
or a pharmaceutically acceptable salt thereof.